Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 19
1999 63
2000 96
2001 186
2002 199
2003 206
2004 369
2005 347
2006 414
2007 473
2008 525
2009 574
2010 662
2011 728
2012 779
2013 853
2014 959
2015 975
2016 926
2017 940
2018 947
2019 1032
2020 1048
2021 1111
2022 1104
2023 135
Text availability
Article attribute
Article type
Publication date

Search Results

13,965 results
Results by year
Filters applied: . Clear all
Page 1
[Trastuzumab and its biosimilars].
Sarosiek T, Morawski P. Sarosiek T, et al. Pol Merkur Lekarski. 2018 May 25;44(263):253-257. Pol Merkur Lekarski. 2018. PMID: 29813044 Review. Polish.
Trastuzumab is a monoclonal antibody used as a standard treatment for breast and metastatic gastric cancer when the cancer cells overexpress HER2, a membrane-bound receptor activated by EGF family of ligands. ...Clinically effective biosimilars may expand patient access to
Trastuzumab is a monoclonal antibody used as a standard treatment for breast and metastatic gastric cancer when the cancer cells over
Trastuzumab Deruxtecan: First Approval.
Keam SJ. Keam SJ. Drugs. 2020 Apr;80(5):501-508. doi: 10.1007/s40265-020-01281-4. Drugs. 2020. PMID: 32144719 Review.
Trastuzumab deruxtecan (ENHERTU()), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Dai
Trastuzumab deruxtecan (ENHERTU()), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the
Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J, Park YH. Lee J, et al. Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26. Future Oncol. 2022. PMID: 34823373 Review.
Trastuzumab deruxtecan (T-DXd, DS-8201), an anti-HER2 antibody-drug conjugate, has shown significant clinical benefits in HER2+ metastatic breast cancer patients. ...It can selectively target HER2-expressing tumor cells. In a recent clinical trial, trastuzumab derux
Trastuzumab deruxtecan (T-DXd, DS-8201), an anti-HER2 antibody-drug conjugate, has shown significant clinical benefits in HER2+ metas
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. Cameron D, et al. Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. Lancet. 2017. PMID: 28215665 Free PMC article. Clinical Trial.
Estimates of 10-year disease-free survival were 63% for observation, 69% for 1 year of trastuzumab, and 69% for 2 years of trastuzumab. 884 (52%) patients assigned to the observation group selectively crossed over to receive trastuzumab. ...The incidence of s …
Estimates of 10-year disease-free survival were 63% for observation, 69% for 1 year of trastuzumab, and 69% for 2 years of trastuz
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. Rugo HS, et al. JAMA Oncol. 2021 Apr 1;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932. JAMA Oncol. 2021. PMID: 33480963 Free PMC article. Clinical Trial.
The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation. ...RESULTS: A total of 536 patients were randomized to receive margetuximab (n = 266) or trastuzumab (n = 270). The m …
The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase imm …
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, Chen L, Zhu Y, Guo C, Shi J, Yu D. Xu Z, et al. Eur J Med Chem. 2019 Dec 1;183:111682. doi: 10.1016/j.ejmech.2019.111682. Epub 2019 Sep 6. Eur J Med Chem. 2019. PMID: 31563805 Review.
Its antibody (trastuzumab) is derived from Herceptin with annual sales of more than $6 billion. ...This paper describes the mechanism of action and the biochemical characteristics of different parts and preclinical and clinical progress of trastuzumab deruxtecan(DS- …
Its antibody (trastuzumab) is derived from Herceptin with annual sales of more than $6 billion. ...This paper describes the mechanism …
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A, Rijavec E, Grossi F. Indini A, et al. Int J Mol Sci. 2021 Apr 30;22(9):4774. doi: 10.3390/ijms22094774. Int J Mol Sci. 2021. PMID: 33946310 Free PMC article. Review.
HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are no approved HER2-targeted therapies with these indications. Trastuzumab deruxtecan (T-DXd) is a novel HER2-directed antibody d …
HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, the …
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Tsurutani J, et al. Cancer Discov. 2020 May;10(5):688-701. doi: 10.1158/2159-8290.CD-19-1014. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213540 Free PMC article. Clinical Trial.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC 1+), non-breast/non-gastric or HER2-mutant solid tumors from a phase I trial (NCT02564900 …
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in …
Trastuzumab Deruxtecan for Breast Cancer.
Zheng F, Du F, Yuan P. Zheng F, et al. N Engl J Med. 2022 Jun 16;386(24):2346-2347. doi: 10.1056/NEJMc2205309. N Engl J Med. 2022. PMID: 35704495 No abstract available.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Tolaney SM, et al. J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2. J Clin Oncol. 2021. PMID: 34077270 Clinical Trial.
PURPOSE: The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients with stage I human e …
PURPOSE: The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclita …
13,965 results
You have reached the last available page of results. Please see the User Guide for more information.